psoriasis vulgaris research hub

A multicenter, Phase 1b, double-blind, placebo-controlled study to evaluate the safety and tolerability, and the efficacy of si-544 in adults with psoriasis vulgaris or psoriatic arthritis

This study is testing a new medicine, si-544, for adults with psoriasis or psoriatic arthritis. It's a first-step study to check if the medicine is safe and if it helps with these conditions. Some people will get the real medicine, others a dummy treatment.

U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing

The U3P study is looking at how a medicine called RINVOQ (upadacitinib) helps people with psoriatic arthritis pain. Researchers will check brain scans to see how the pain changes over time, aiming to understand how this treatment works in the body.

Investigating the role of JAK inhibition in achieving and maintaining disease remission in psoriatic arthritis (PsA).

This study looks at how well a medicine called XELJANZ works for psoriatic arthritis. It checks if the medicine can help people get into remission and stay there. Researchers will also see how it affects symptoms like joint and skin problems over time.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

This study looks at a new medicine called tildrakizumab (also known as Ilumetri) for people with psoriatic arthritis who haven't responded well to other treatments. It aims to see if tildrakizumab can help reduce joint pain and swelling better than a dummy medicine.

A stratification trial to determine key immunological factors predicting Tofacitinib efficacy in Psoriatic Arthritis (PsA); TOFA-PREDICT

This study, called TOFA-PREDICT, looks at how a medicine called Tofacitinib works for people with Psoriatic Arthritis. Researchers want to understand why it helps some people more than others by looking at their body's chemistry before and during treatment.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)

This study is testing a new medicine, Ilumetri, for adults with active psoriatic arthritis who haven’t used similar medicines before. Researchers want to see if it helps reduce symptoms like joint pain and swelling, and if it’s safe to use. Half the people will get the medicine, and half will get a dummy injection.

A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS

This study is looking at the long-term safety and effectiveness of a medicine called bimekizumab for people with psoriatic arthritis. It checks how well the medicine works over time and if it causes any side effects, building on previous studies.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

This study is comparing two versions of a drug called upadacitinib. It's to check if a new version works the same way in the body as the existing one. Healthy adults volunteer for this study.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.

This study compares a new version of upadacitinib (a medicine for arthritis and other conditions) from Sun Pharma with the existing Rinvoq medicine. Doctors want to check if both versions work the same way in healthy adults after they’ve eaten.

An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

This study compares two versions of a 15mg upadacitinib tablet in healthy adults. It's to see if a new tablet works the same way in the body as an existing one, for conditions like rheumatoid arthritis and Crohn's disease.

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

This study looks at a new drug, zasocitinib, for adults with psoriatic arthritis. It aims to see how well it works compared to a dummy drug. We're interested in people who have or haven't tried certain other treatments before.

HIPPOCRATES Prospective Observational Study

This study aims to find out why some people with psoriasis get psoriatic arthritis. We'll use questionnaires and some blood samples to help identify those at risk. Our goal is to one day prevent arthritis from developing.

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

This study compares a new medicine, risankizumab, with a dummy treatment (placebo) for people with active psoriatic arthritis. It checks how safe and effective risankizumab is, especially for those who haven't responded well to other treatments.

Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis

This study looks at a new way to reduce long-lasting pain in people with psoriatic arthritis. It explores using a special type of brain stimulation called rTMS to 'rewire' parts of the brain that link pain and the body's immune system, aiming for lasting pain relief.

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

This study is looking at a new medicine called deucravacitinib for people with active psoriatic arthritis who haven't tried certain other strong medicines for their condition before. It aims to see how well it works and if it's safe.

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

This study is testing a new medication called deucravacitinib for active psoriatic arthritis. It compares the new drug to a dummy pill to see if it helps people feel better and if it's safe. It's for people new to certain treatments or who have tried one specific type before.

IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY.

This study looks at how a medicine called Taltz helps people with psoriatic arthritis that hasn't responded well to other treatments. Researchers are checking if they can identify certain body signals (biomarkers) to predict who will benefit most from Taltz.

A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)

This study looks at how much of the medicine, Bimzelx, gets into breast milk. It's for mothers with conditions like psoriasis or arthritis who are treated with Bimzelx, to understand if it's safe for their babies.

DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMIDS) USING SYSTEMS APPROACHES

This study looks at a new medicine called Tyenne for people with Psoriatic Arthritis or Rheumatoid Arthritis. It wants to see if this medicine helps reduce symptoms and if combining it with other treatments works better to put the disease into remission.

A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

This study is looking into a new medicine, Zasocitinib, for people with psoriatic arthritis. It's checking its long-term safety and how well it helps their symptoms. Participants will either get Zasocitinib or a dummy medicine.

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

This study is testing a new medicine called bimekizumab for adults with active psoriatic arthritis. It compares bimekizumab to another medicine, risankizumab, and a dummy treatment (placebo), to see how well it works and if it's safe over 16 weeks.

22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis

Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms

This study investigates how inflammation, particularly involving a protein called IL-17, might link certain skin and joint conditions like psoriasis and psoriatic arthritis with depression. Researchers will use special brain scans and different anti-inflammatory medicines to understand and potentially improve depression symptoms.